Discover
CRDL
Cardiol Therapeutics Inc.
1.50
15 x 1.49
37 x 1.50
bid
ask
+
0.03
2.04%
12:33 PM
timesize
| Ytd | 57.23% | |
| 1y | 45.63% |
1.46
day range
1.50
0.88
52 week range
1.71
| Open | 1.49 | Prev Close | 1.47 | Low | 1.46 | High | 1.50 | Mkt Cap | 172.91M |
| Vol | 350.76K | Avg Vol | 620.55K | EPS | -0.28 | P/E | -5.34 | Forward P/E | -4.03 |
| Beta | 0.72 | Short Ratio | 1.37 | Inst. Own | 9.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.14 | 200-d Avg | 1.13 | 1yr Est | 8.70 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.1 | -0.13 | -0.03 | -30.00% |
| 2024-08-12 | 2024-06 | -0.1 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.1 | -0.07 | 0.03 | 30.00% |
| 2024-05-14 | 2024-03 | -0.06 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.06 | -0.1 | -0.04 | -66.67% |
| 2024-04-01 | 2023-12 | 0 | -0.09 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-26 | Roth MKM | Upgrade | Buy | |
| 2024-06-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Tejara Capital Ltd | 1.77M | 2.21M | 2.17% |
| 2024-09-29 | AdvisorShares Investments, LLC | 1.17M | 1.46M | 1.43% |
| 2024-09-29 | MMCAP International, Inc. SPC | 795.63K | 994.53K | 0.97% |
| 2024-09-29 | Lion Street Advisors, LLC | 273.28K | 341.60K | 0.33% |
| 2024-09-29 | Foundations Investment Advisors, Llc | 161.95K | 202.44K | 0.20% |
| 2024-09-29 | MGO One Seven, LLC | 100.00K | 125.00K | 0.12% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 1.05M | 1.31M | 1.28% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 52.44K | 65.54K | 0.06% |